Abstract
Background
Methods
Results
Conclusion
Notes
AUTHOR CONTRIBUTIONS
Conception or design: S.A., J.H.O., C.M.S. Acquisition, analysis, or interpretation of data: S.A., C.M.S., E.J., D.K., S.J.J. Drafting the work or revising: H.J., S.A., J.H.O., C.M.S., E.J., J.L. Final approval of the manuscript: H.J., S.A., J.H.O., C.M.S., E.J., D.K., S.J.J., J.L.
ACKNOWLEDGMENTS
REFERENCES
Table 1.
Characteristic | Progressor to diabetes (n=207) | Non-progressor (n=4,365) | P value |
---|---|---|---|
Female sex | 121 (58.50) | 2,731 (62.60) | 0.263 |
Age, yr | 62.39±9.48 | 59.48±9.27 | <0.001a |
Employed insurance | 132 (63.80) | 2,639 (60.50) | 0.379 |
Smoking | 77 (37.20) | 1,408 (32.30) | 0.159 |
Hypertension | 90 (43.50) | 1,203 (27.06) | <0.001a |
BMI, kg/m2 | 24.95±2.81 | 23.84±2.97 | <0.001a |
Waist circumference, cm | 85.24±8.42 | 82.18±8.80 | <0.001a |
Fasting plasma glucose, mg/dL | 102.29±11.26 | 94.63±9.40 | <0.001a |
Hemoglobin, g/dL | 13.93±1.52 | 13.76±1.41 | 0.096 |
Systolic BP, mm Hg | 118.62±18.33 | 119.13±18.16 | 0.692 |
Diastolic BP, mm Hg | 76.59±10.63 | 77.08±10.70 | 0.521 |
Total cholesterol, mmol/L | 197.17±36.18 | 194.72±35.36 | 0.330 |
Fasting insulin, µIU/mL | 11.69±8.73 | 9.42±5.25 | <0.001a |
HDL-C, mmol/L | 48.15±10.98 | 48.79±11.39 | 0.425 |
Triglycerides, mmol/L | 134.51±91.57 | 135.29±104.54 | 0.916 |
HOMA-IR | 3.02±2.52 | 2.23±1.39 | <0.001a |
HOMA-β | 110.55±66.93 | 113.52±64.17 | 0.516 |
HOMA-IR/HOMA-β status | <0.001a | ||
HOMA-IR (low), HOMA-β (high) | 14 (6.80) | 645 (14.80) | |
HOMA-IR (low), HOMA-β (low) | 52 (25.10) | 1,492 (34.20) | |
HOMA-IR (high), HOMA-β (high) | 81 (39.10) | 1,589 (36.40) | |
HOMA-IR (high), HOMA-β (low) | 60 (29.00) | 639 (14.60) |
Values are expressed as number (%) or mean±standard deviation. P values were calculated using Student’s t test or chi-square test.
KNHANES, Korea National Health and Nutrition Examination Survey; NHIS, National Health Insurance Service; BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function.
Table 2.
No. | Person-year (IRR) |
Model A |
Model B |
Model C |
||||
---|---|---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |||
HOMA-IR (low), HOMA-β (high) | 14 | 4,159.82 | 1 (Ref) | - | 1 (Ref) | - | 1 (Ref) | - |
HOMA-IR (low), HOMA-β (low) | 52 | 8,439.04 (1.83) | 1.83 (1.02–3.31) | 0.044a | 1.70 (0.94–3.07) | 0.080 | 1.68 (0.93–3.04) | 0.085 |
HOMA-IR (high), HOMA-β (high) | 81 | 10,021.28 (2.40) | 2.40 (1.36–4.23) | 0.003a | 2.31 (1.31–4.07) | 0.004a | 1.81 (1.01–3.22) | 0.045a |
HOMA-IR (high), HOMA-β (low) | 60 | 4,048.49 (4.40) | 4.40 (2.46–7.86) | <0.001a | 4.07 (2.27–7.29) | <0.001a | 3.36 (1.86–6.05) | <0.001a |
Model A: unadjusted; Model B: adjusted for age and sex; Model C: adjusted for age, sex, systolic blood pressure, body mass index, and total cholesterol.
HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; KNHANES, Korea National Health and Nutrition Examination Survey; NHIS-HEALS, National Health Insurance Service-National Health Screening Cohort; IRR, incidence risk ratio; HR, hazard ratio; CI, confidence interval.